Testis-sparing surgery for small testicular masses: what the evidence says about saving the testicle

A small lump found on a scrotal ultrasound used to lead almost automatically to one outcome: radical orchiectomy, meaning the entire testicle is removed. That was the safe play, and for decades it was the only play. But the picture has shifted. A growing body of evidence now supports testis-sparing surgery (TSS) -- also called partial orchiectomy or organ-sparing surgery -- as a legitimate option for carefully selected men with small testicular masses. The question is not whether TSS is real. It is whether you are the right candidate for it, and what the functional and oncological tradeoffs actually look like.

At NoMi Beach Health, we follow the urologic oncology literature closely because the downstream effects -- testosterone production, fertility, and the potential need for hormone replacement -- sit squarely in the integrative men's health work we do every day. If you have been told you have a small testicular mass, this post is designed to help you understand the conversation you should be having with your urologist, and what the evidence says about outcomes.

What counts as a small testicular mass?

Not every lump in the scrotum is a tumor, and not every testicular tumor is the same size or the same risk. The first thing a clinician does is characterize the mass -- where it is, how big it is, whether it is inside or outside the testicle, and what the serum tumor markers show.

Most published TSS protocols define "small" as 20 mm (about three-quarters of an inch) or less in greatest diameter, though some series use a 30 mm cutoff (Bojanic N, et al., 2015, https://pubmed.ncbi.nlm.nih.gov/25678217/). Raw size is only part of the picture. The ratio of tumor volume to total testicular volume matters too -- if the mass takes up more than 30% of the testicle, there may not be enough healthy parenchyma left after excision to justify organ preservation.

Serum tumor markers -- alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactate dehydrogenase (LDH) -- are drawn before any surgery. Elevated markers in the setting of a small mass raise the suspicion for germ cell tumor and change the risk-benefit math. Normal markers do not rule out malignancy, but they point toward a higher probability of a benign lesion, which is relevant because a meaningful share of small incidentally found testicular masses turn out to be benign on final pathology (Vasdev N, et al., 2012, https://pubmed.ncbi.nlm.nih.gov/22508326/).

Who is testis-sparing surgery actually for?

TSS is not a blanket alternative to radical orchiectomy. The AUA and EAU guidelines identify specific clinical situations where organ-sparing surgery is most supported by evidence (AUA Guideline on Testicular Cancer, 2023, https://www.auanet.org/guidelines-and-quality/guidelines/testicular-cancer-guideline; EAU Guidelines on Testicular Cancer, 2023, https://uroweb.org/guidelines/testicular-cancer).

The clearest indication is a man with a solitary testicle -- either because he was born with one or because the contralateral testicle was previously removed -- who has a small mass. Removing the only testicle in that scenario means immediate surgical castration, lifelong testosterone replacement, and permanent infertility. The tradeoff shifts dramatically toward organ preservation if the mass is small and the frozen section is favorable.

Bilateral synchronous testicular tumors are a second strong indication. This is uncommon, but it happens. Bilateral radical orchiectomy is a severe outcome that TSS can sometimes avoid (Heidenreich A, et al., 2001, https://pubmed.ncbi.nlm.nih.gov/11306217/).

The third scenario -- and increasingly the most common one as ultrasound use has expanded -- is the incidentally discovered small mass in a man with a normal contralateral testicle. This is more nuanced. Some urologists offer TSS here; others prefer radical orchiectomy because the contralateral testicle preserves hormonal function regardless. Patient values, fertility goals, and surgeon experience all weigh into that conversation.

Men who are NOT good candidates include those with large tumors, high tumor-to-testis volume ratios, markedly elevated tumor markers suggesting aggressive germ cell disease, or who simply prefer the certainty of radical orchiectomy after a clear discussion of the options.

The role of intraoperative frozen section

The technical cornerstone of TSS is intraoperative frozen section analysis. Once the surgeon exposes the mass, a pathologist examines a tissue sample in real time -- typically while the patient is still on the table. If the frozen section shows benign tissue, the excision proceeds and the testicle is closed. If it shows malignancy in a solitary testicle, the surgeon and patient (who ideally discussed this scenario pre-operatively) decide whether to proceed with radical orchiectomy or close and consider adjuvant radiation.

Frozen section is not a perfect test. Reported sensitivity for detecting malignancy runs above 90% in published series, but false negatives occur (Elert A, et al., 2002, https://pubmed.ncbi.nlm.nih.gov/12234505/). That is why permanent pathology from the full specimen is still mandatory, and why surveillance imaging continues after TSS regardless of the frozen section result. Frozen section is a real-time guide, not a final answer.

The practical implication: the discussion about what to do if the frozen section comes back positive has to happen before the patient goes to sleep. Informed consent for TSS should include explicit scenarios for each possible intraoperative finding.

Oncological outcomes: what does the evidence actually show?

A 2025 systematic analysis published in the Journal of Urology (Silay MS, et al., 2025, https://pubmed.ncbi.nlm.nih.gov/42365841/) reviewed functional and oncological outcomes across published TSS series. The findings reinforce what smaller institutional reports have suggested for years: in well-selected patients with small masses, TSS delivers local recurrence rates that are low and, for benign lesions, largely comparable to the complete removal of the testicle in terms of cancer control.

For men whose final pathology shows germ cell tumor after TSS -- particularly testicular intraepithelial neoplasia (TIN), also called carcinoma in situ -- adjuvant low-dose radiation to the remnant testicle is a common next step. Radiation in this context effectively sterilizes the remaining tissue against TIN, which carries a high progression risk if untreated (Dieckmann KP and Loy V, 1996, https://pubmed.ncbi.nlm.nih.gov/8622030/). The tradeoff is that radiation to the testicle damages Leydig cells over time, which means the hormonal benefit of organ preservation may be partially or fully eroded for men who require adjuvant radiation.

The honest summary: TSS without adjuvant radiation, in men whose final pathology is benign or very low-risk, offers excellent local control. TSS followed by adjuvant radiation trades some of the hormonal upside for better oncological security. The right path depends on what the pathology shows.

Functional outcomes: testosterone and fertility

This is the part of the conversation that connects directly to what we see in our practice. Radical orchiectomy of one testicle does not automatically cause hypogonadism -- the remaining testicle often compensates -- but it does shift the hormonal reserve downward. Studies have shown that a meaningful proportion of men who undergo unilateral orchiectomy for testicular cancer end up with testosterone levels in the low-normal to frankly hypogonadal range, particularly as they age or if the contralateral testicle has any degree of dysfunction (Bieniek JM, et al., 2016, https://pubmed.ncbi.nlm.nih.gov/26919714/).

TSS, by preserving Leydig cell mass in the operated testicle, aims to maintain endogenous testosterone production. For men with bilateral disease or a solitary testicle, this is the difference between physiological testosterone and surgical castration requiring lifelong replacement. For men with a normal contralateral testicle, the hormonal benefit is more modest -- but it is still a benefit, and it compounds over decades.

Fertility follows a similar logic. Spermatogenesis in the preserved testicular tissue is possible after TSS, though adjuvant radiation significantly impairs it. Men who receive adjuvant radiation to the remnant testicle should be counseled that fertility through that testicle is unlikely after treatment. Sperm banking before any intervention -- surgery or radiation -- is a conversation worth having early.

If you want to understand the broader picture of when testosterone replacement therapy is and is not the right move, our post on signs of low testosterone and our concierge men's health after 35 overview lay out the clinical framework we use.

What surveillance looks like after TSS

Testis-sparing surgery is not a one-and-done procedure. The follow-up protocol matters as much as the operation itself. Standard elements of post-TSS surveillance include:

• Scrotal ultrasound at regular intervals (typically every 6 to 12 months in the first few years, then annually)
• Serum tumor markers (AFP, beta-hCG, LDH) at each follow-up visit
• Cross-sectional imaging of the abdomen and pelvis if the final pathology shows germ cell tumor
• Testosterone levels, especially if adjuvant radiation was administered or if symptoms of hypogonadism emerge

The surveillance schedule is individualized based on pathology. A man whose final pathology shows a simple epidermoid cyst -- a benign entity -- needs far less intensive imaging than a man whose pathology shows a seminoma managed with organ-sparing surgery. This is not a one-protocol-fits-all situation.

If surveillance imaging picks up a local recurrence, completion orchiectomy is the standard next step. TSS is not a bridge to avoiding surgery forever -- it is an attempt to preserve function while maintaining oncological safety, with radical orchiectomy remaining available as a rescue.

How this fits into an integrative men's health approach

At NBH, we are not urologic surgeons -- the decision to pursue TSS versus radical orchiectomy belongs to a urologic oncologist with the imaging, the pathology, and the patient in front of them. What we do is help men understand the downstream hormonal and functional consequences of those decisions, and build a plan for what comes after.

If you have had a radical orchiectomy and your testosterone has drifted low, that is a clinical conversation we know well. If you are in surveillance after TSS and wondering whether your hormone levels need attention, we can work through that with you. If you have a newly discovered testicular mass and want to understand the landscape before your urology appointment, we can help you frame the right questions.

The connective tissue between this topic and the broader men's health work we do is straightforward: the testicle is not just a reproductive organ. It is a major source of testosterone, and testosterone touches muscle, bone, metabolism, mood, and cardiovascular health in ways that matter over a lifetime. Preserving testicular tissue when it is safe to do so is not vanity -- it is physiology.

For men navigating the intersection of testicular health, hormone levels, and long-term wellbeing, our men's health services page outlines how we approach this work. If you are ready to talk through your specific situation, book a new-patient visit at nomibeach.health or call us at (786) 744-5152. We will look at your labs, your history, and your goals -- then give you a straight answer.